Guillaume brings over 20 years of experience in early and late-stage small molecule drug discovery in biotech/pharma.

Prior to joining Rewind in 2020, he co-founded Pragma Therapeutics, where he served as CSO and was in charge of the research and development of Pragma’s portfolio. From 2015 to 2018, he was Senior Director of Chemistry at Prexton Therapeutics, and, from 2004 to 2013, he served as Group Leader and subsequently as Research Director at Addex Therapeutics, where he led several preclinical programs. During his tenure at Addex, he was also responsible for developing strategic scientific partnerships and technological platforms, integrating modern techniques for the identification, characterization, and optimization of preclinical molecules for novel targets and new indications. Prior to Addex, he joined the R&D division of Janssen in France in 2000, where he focused on small molecule drug discovery and advanced several research programs in oncology, virology and CNS disorders.

Guillaume holds a PhD in Organic Chemistry from the University of Rouen (France) and is co-author of more than 25 patents and peer-reviewed articles.

This website uses cookies to ensure you get the best experience on our website. Get more details by clicking on the Button below.